Simple and complex carotid paragangliomas. Three decades of experience and literature review

Lozano, Francisco; Muñoz, Ángel Sánchez-Anguita; Heras, José A. de las; González‐Porras, José Ramón

doi:10.1002/hed.26421

Cited by 11 publications

(8 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We demonstrated that surgical treatment without preoperative embolization is safe and effective even in large tumors. [30] 2016 47 45 (34-56) 33% 53% 14% 18% 6.4% 0% Lamblin et al [31] 2011 54 49 (38.2-57.7) 31.2% 46.3% 22.2% 47.6% 5.6% 0% Metheetrairut et al [21] 2015 38 36.9 (15-59) 22.5% 35% 42.5% 20% 5% 0% Fruhmann et al [15] 2013 50 54.5 (17-80) 20.6% 44.4% 34.9% 20.6% 2% 0% Torrealba et al [32] 2016 30 45.5 (18-75) 16.7% 63.3% 20% 23% 0% 0% Lozano et al [33] 2020 50 60.3 (33-78) 18% 16.3% 2% 6% Zhang et al [34] 2018 29 46 27.6% 55.2% 17.2% 27.6% 0% 0%…”

Section: Discussionmentioning

confidence: 99%

Carotid body tumor encounters over a two-decade period in an academic hospital

et al. 2022

View full text Add to dashboard Cite

Carotid body tumors (CBTs) are rare and mostly benign. Research outcomes usually arise from single-center data. We conducted this study to present the characteristics and outcomes of patients who underwent surgical resection of CBT at our hospital over the past 20 years. In this retrospective review, the records of CBTs in our hospital were reviewed between 1998 and 2021. All patients who underwent CBT resection were included. The follow-up period was 12 months. A total of 44 CBTs were treated in our hospital. The male-to-female ratio was 1:2.4. Only 4.5% of patients had Shamblin I tumors. Patients with Shamblin II and III tumors were 56.8% and 38.6%, respectively. Duplex scan was used to diagnose CBT in all of the patients. The majority of our patients (97.7%) did not receive any preoperative embolization despite an average tumor size of 4.9 cm. Cranial nerve injuries were observed in 29.5% of cases. Meanwhile, stroke was reported in only two cases (4.5%). No deaths were encountered. Surgery is the definitive treatment for CBT. Size and local extension appear to be the main reasons for adverse events rather than surgical techniques. Our results are consistent with those of previously published studies. Good outcomes are expected in high-volume centers with appropriate preoperative imaging.

show abstract

Section: Discussionmentioning

confidence: 99%

Carotid body tumor encounters over a two-decade period in an academic hospital

et al. 2022

View full text Add to dashboard Cite

show abstract

“…95,96 Surgery remains the most common strategy for managing CBTs. 8,9,48,98,99 It is associated with long-term control greater than 95%. 48,98 The Shamblin classification has long been used to predict operative morbidity and mortality in CBTs.…”

Section: Isolated Cbtsmentioning

confidence: 99%

Contemporary management of paragangliomas of the head and neck

Cleere

Martin-Grace

Gendre

et al. 2021

Laryngoscope Investig Oto

View full text Add to dashboard Cite

Head and neck paragangliomas (HNPGLs) are rare neuroendocrine tumors typically arising from nonsecretory head and neck parasympathetic ganglia. Historically thought of as aggressive tumors that warranted equally aggressive surgical intervention, evidence has emerged demonstrating that the vast majority of HNPGLs are slow growing and indolent. It is also now recognized that a large proportion of HNPGLs are hereditary with succinate dehydrogenase gene mutations typically implicated.These recent advances have led to significant changes in the way in which clinicians investigate and treat HNPGLs with most now opting for more conservative treatment strategies. However, a proportion of patients present with more aggressive disease and still require nonconservative treatment strategies. Recent studies have sought to determine in which groups of patients the morbidity associated with treatment is justified. We summarize the recent advances in the understanding and management of these tumors and we provide our recommendations regarding the management of HNPGLs.

show abstract

“…Among these articles, 20 (158 patients) included 5 or more patients (Table 1) 18–39 and were considered for the proportion MA. The remaining 112 studies (179 patients), represented by case reports or case series with <5 patients, are reported in Table S1 3,40–152 …”

Section: Resultsmentioning

confidence: 99%

Malignant carotid body tumors: What we know, what we do, and what we need to achieve. A systematic review of the literature

Piazza,

Lancini,

Tomasoni

et al. 2024

Head & Neck

View full text Add to dashboard Cite

Malignant carotid body tumors (MCBT) are rare and diagnosed after detection of nodal or distant metastases. This systematic review (SR) focuses on MCBT initially approached by surgery. Preferred Reporting Items for SR and Meta‐Analysis (MA) guided the articles search from 2000 to 2023 on PubMed, Scopus, and Web of Science. Among 3548 papers, 132 (337 patients) were considered for SR; of these, 20 (158 patients) for MA. Malignancy rate was 7.3%, succinate dehydrogenase (SDH) mutation 17%, age at diagnosis between 4th and 6th decades, with a higher prevalence of females. MCBTs were mostly Shamblin III, with nodal and distant metastasis in 79.7% and 44.7%, respectively. Malignancy should be suspected if CBT >4 cm, Shamblin III, painful or otherwise symptomatic, at the extremes of age, bilateral, with multifocal disease, and SDHx mutations. Levels II–III clearance should be performed to exclude nodal metastases and adjuvant treatments considered on a case‐by‐case basis.

show abstract

Simple and complex carotid paragangliomas. Three decades of experience and literature review

Cited by 11 publications

References 66 publications

Carotid body tumor encounters over a two-decade period in an academic hospital

Carotid body tumor encounters over a two-decade period in an academic hospital

Contemporary management of paragangliomas of the head and neck

Malignant carotid body tumors: What we know, what we do, and what we need to achieve. A systematic review of the literature

Contact Info

Product

Resources

About